Unresectable or metastatic treatment:
1.Patient must not have received prior treatment with a PD-1 / PD-L1 inhibitor in the metastatic/unresectable setting for the same condition, e.g. lung cancer.
2.Patient must not have experienced disease progression whilst on adjuvant/neo-adjuvant PD-1/ PD-L1 inhibitor treatment or disease recurrence within 6 months of completion of adjuvant/neo-adjuvant PD-1 / PD-L1 inhibitor treatment.
3.Treatment breaks may be considered, if deemed clinically appropriate, where a patient is in remission or has stable disease. Treatment can recommence, where deemed clinically appropriate, if the patient has not experienced disease progression or recurrence within 6 months of stopping of treatment.
4.This guidance may be superseded by the specific reimbursed licensed indication as detailed in the INDICATIONS FOR USE section of the NCCP regimen
Adjuvant or neo-adjuvant treatment:
1.Patient must not have received prior treatment with a PD-1 / PD-L1 inhibitor in the neo-adjuvant or adjuvant setting for the same condition.
2. This guidance may be superseded by the specific reimbursed licensed indication as detailed in the INDICATIONS FOR USE section of the NCCP regimen
